Fast‑Track Psychedelics: New Rules for Treating Depression and PTSD

"President Trump recently signed an order that urges the FDA and other agencies to speed up research on psychedelics, which are still illegal under federal law. The agency has given priority review vouchers to two firms working on psilocybin, the key ingredient in magic mushrooms, for severe depression that does not respond to other treatments. A third voucher went to a company developing methylone, a chemical similar to MDMA, for post‑traumatic stress disorder. The vouchers do not guarantee approval; they simply shorten the review time from months to weeks. \n\nThe move comes amid growing support for these substances among Trump’s base, including veterans and followers of the Make America Healthy Again campaign led by Health Secretary Robert Kennedy Jr. Kennedy has publicly promised that psychedelics could be available for difficult psychiatric conditions within a year, and several of his aides have expressed enthusiasm for the drugs. \n\nThe FDA’s special treatment may bring renewed scrutiny of its National Priority Voucher program, as critics argue that the vouchers have favored companies with political ties to the White House and those willing to lower prices. Meanwhile, a separate FDA decision allows initial testing of an ibogaine‑related drug for alcohol use disorder.Ibogaine, derived from an African shrub, has a controversial safety record but is popular among veterans seeking treatment for trauma and addiction. \n\nThe involvement of high‑profile figures such as podcaster Joe Rogan, who met with the president about ibogaine, highlights how political influence may accelerate drug approval processes. Rogan’s endorsement of the substance just before the 2024 election was noted by White House aides as a potential factor in his campaign success. \n\nAlthough psychedelics like LSD, psilocybin and MDMA are classified as Schedule I substances with no accepted medical use, a wave of small companies—often backed by Silicon Valley investors—has entered the field. Tech billionaire Peter Thiel, who has donated to both Trump and Vice President JD Vance, is one example of an investor supporting psychedelic research. \n\nThe policy shift reflects a broader trend of reexamining the legal status of mind‑altering drugs and their potential therapeutic benefits. However, questions remain about safety, regulation, and the influence of politics on scientific progress. "